Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamta Garg

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 4, 2021
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONEMaria-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
The New England Journal of Medicine|December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaMaría-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
The New England Journal of Medicine|April 13, 2022
Rilzabrutinib, an Oral BTK Inhibitor, in Immune ThrombocytopeniaDavid J Kuter, Merlin Efraim, Jiri Mayer, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 4, 2021
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONEMaria-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
The New England Journal of Medicine|December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaMaría-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
The New England Journal of Medicine|April 13, 2022
Rilzabrutinib, an Oral BTK Inhibitor, in Immune ThrombocytopeniaDavid J Kuter, Merlin Efraim, Jiri Mayer, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Pageof 5